Literature DB >> 31908543

Anemia And Associated Factors Among Adult People Living With HIV/AIDS Receiving Anti-Retroviral Therapy At Gedeo Zone, SNNPR, Ethiopia, 2018.

Wagaye Alemu Zenebe1, Adane Tesfaye Anbese1, Tinsae Shemelise Tesfaye1.   

Abstract

BACKGROUND: Anemia is one of the most common blood abnormalities in people with HIV. The incidence of anemia ranges from 10% in people who have no HIV symptoms to 92% among individuals who have advanced AIDS. Anemia which is also one of the major challenges among HIV patients can lead to impaired physical functioning, psychological distress, poor quality of life, accelerated disease progression, and shorter life expectancy. There are different reports that show a large number of patients with both anemia and HIV/AIDS in Ethiopia. However, the burden of anemia among those HIV/AIDS patients receiving ART is not fully understood in Gedeo zone health institutions. Hence, this study is designed to assess the prevalence of anemia and associated factors among adult HIV/AIDS clients receiving ART at Gedeo zone health institutions, SNNPR, Ethiopia.
METHODS: An institution-based cross-sectional study was conducted in Gedeo zone health institutions from November 21 2017 to January 30, 2018. The systematic random sampling technique was used to recruit the study participants. The hematocrit level was used to determine anemic status. Data were entered into EPI info version 7 and transferred to STATA version 12.0 for analysis. In order to identify factors associated with anemia, a multivariable logistic regression analysis was employed. RESULT: A total of 422 patients were included with a mean age of 33.85 (SD = ±9. 12) years. The prevalence of anemia was 34.8% (95% CI 30.1-39.8), while about 7.4%, 14.3%, and 13.1% of the patients had severe, moderate, and mild anemia, respectively. The mean hemoglobin was 14.6 (SD=±10. 8), (95% CI 13.6_15.8). INH/Isoniazid prophylaxis (OR =1.8 [95% CI: 1.1, 2.9]) and bedridden functional status (OR =5.48 [95% CI: 1.25, 23.8]) were determinants of anemia in this study.
CONCLUSION: In this study, a large number of pateients had anemia (34.8%) with the majority of them having a moderate form. Functional status and using INH prophylaxis were determinant factors of anemia.
© 2019 Zenebe et al.

Entities:  

Keywords:  HIV/AIDS; anemia; hematocrit level; prevalence

Year:  2019        PMID: 31908543      PMCID: PMC6927561          DOI: 10.2147/HIV.S220461

Source DB:  PubMed          Journal:  HIV AIDS (Auckl)        ISSN: 1179-1373


Introduction

Anemia is the most common hematological disorder. We define anemia to be when hemoglobin (Hb) and hematocrit (HCT) levels are below the normal reference range according to WHO criteria. In males, anemia is diagnosed when Hb is <13 g/dL and HCT is <39%, whereas in females, anemia is when Hb is <12 g/dL and HCT is <36%.1 Twenty percent of all hospital admissions among the elderly are due to anemia.2 Anemia may be caused by nutrient deficiencies (iron, folic acid and vitamin B12), sickle cell disease, AIDS, malaria, hookworm infection, and other infections.3 Anemia is one of the most common blood abnormalities in people with HIV. The incidence of anemia ranges from 10% in people who have no HIV symptoms to 92% in individuals who have advanced AIDS.4 The hematological manifestations of HIV infection are complications of the disease which may be clinically important in patients. An obvious cause of anemia in patients with HIV infection is blood loss. Other than blood loss, HIV-associated anemia may cause decreased red blood cell/RBC production, increased RBC destruction and ineffective RBC production.5,6,7 Anemia which is also one of the major challenges among HIV patients can lead to impaired physical functioning, psychological distress, poor quality of life, accelerated disease progression, and shorter life expectancy.5 Although anemia can occur at any stage of HIV infection, its severity is correlated with progression of the HIV disease stage. A study conducted in the very early years of HIV discovery shows the overall prevalence of anemia to be about 28% among people with HIV infection in the pre-AIDS stage of the disease, whereas it could reach as high as 71% in the advanced or AIDS stage of the HIV disease.9 According to reports, the prevalence of anemia among adult HIV patients taking ART ranges between 23% and 50% globally4,6,10 and between 24% and 58% in Africa.11,12 Generally, the prevalence of anemia tends to be higher in ART-naïve patients compared to ART users.18,19 In Ethiopia, the prevalence of anemia among ART-naïve adult HIV patients was reported to reach up to 35%.13 A study done 3 years ago in the southwest part of Ethiopia has shown the prevalence of anemia to be 29.9% and 16.2% among ART-naïve and ART-experienced HIV patients, respectively.14 There are different reports that show a large number of both HIV/AIDS and anemia in Ethiopia. However, the burden of anemia among people living with HIV/AIDS and receiving ART is not fully understood in Gedeo zone health institutions. Hence, this study is designed to assess the prevalence of anemia and associated factors among adult HIV/AIDS clients receiving ART at Gedeo zone health institutions, SNNPR, Ethiopia.

Materials And Methods

Study Setting And Design

Multicenter institution–based cross-sectional study was conducted in selected governmental health institutions in Gedeo zone, SNNP regional state of Ethiopia from March to April, 2018 . The zone has 8 werdas and 2 city administrations. There are 38 health centers in the zone and 4 hospitals, including Dilla University Referral Hospital, but only the 7 health centers and 4 hospitals have ART services.

Study Population

The study population for this study was all HIV-positive adults aged 15 years and above who ever started first-line ART at the selected health institutions between February 2010 and 2017 in Gedeo zone, SNNP, Ethiopia. All HIV-positive adults (age ≥15 years) on ART for at least 6 months were included, because adequate exposure to treatment is considered if the patient takes the drug for at least 6 months. It is also related to the time in which the treatment started to suppress the virus and the immunity becomes reconstituted. Patients who have less than two follow-up CD4 counts, transferred in and who had incomplete information about the outcome variable were excluded. The sample size was 422; it was calculated using sample size calculation formula taking confidence level=95%, power=80%, prevalence of anemia among HIV patients=52.3%15 and by adding 10% non-response rate.

Data Collection Instruments And Procedure

Socio-demographic details such as age, gender, residence, employment status, level of education and marital status were collected using interviewer-administered questionnaire. A standardized data extraction checklist was prepared by the investigators in English and was collected from patient chart and log book. The 2011 World Health Organization (WHO) report on the Hb concentration level to diagnose anemia was used in the hospital.16 Accordingly, anemia for males is defined as the Hb concentration <13 g/dL (11.0–12.9 g/dL=mild; 8.0–10.9 g/dL moderate, and <8.0 g/dL=severe), whereas anemia for females is defined as Hb <12.0 (11.0–11.9 g/dL=mild, 8.0–10.9 g/dL=moderate, and <8.0 g/dL=severe). Five BSC nurses who had experience in working at the ART clinic participated in the data collection process after one-day training and were supervised by 4 supervisors. The data clerks and card room workers supported them by identifying the cards of patients.

Data Processing And Analysis

Data were entered into EPI info version 7 and transferred to STATA version 12.0 for analysis. Descriptive and summary statistics were carried out. The data analysis ranged from the basic description of outcomes to the identification of statistically significant associations. Accordingly, simple frequencies, measure of central tendencies and measure of dispersions were computed. Bivariate analysis and multiple logistic models were used to show the relationship between anemia and various associated factors. Finally, all explanatory variables that were significantly associated with the outcome variable in the bivariate analyses (P < 0.25) were entered into the multivariable logistic regression model to identify independent predictors of anemia. The adjusted odds ratio (AOR) with 95% confidence interval (CI) was calculated to show the strength of association. In multivariable analysis, variables with a P-value of <0.05 were considered as statistically significant.

Results

Socio-Demographic And Clinical Characteristics

In this study, a total of 422 patients were included. The majority of the patients (56.7%) were females and 42.3% of the study participants were in the age group of 40–49 years with a mean age of 33.85 (SD = ±9. 12) years. Most of the study participants (68.8%)functional status was working (Table 1).
Table 1

Socio-Demographic And Clinical Characteristics Of Adult HIV Patients On First-line ART In Gedeo Zone 2018

VariableCategoryFrequencyPercent
Age<30 years13131.5
30–39 years17642.3
40–49 years8019.2
>50 years297
Educational statusNo formal education11226.5
Primary15135.8
Secondary and above13231.3
4410.48
Occurrence OIYes20248.6
No19847.6
OccupationUnemployed28968.5
Employed368.5
Merchant368.5
CD4(cells/mm3)<20018143.5
200–49915537.3
>5008019.2
Functional statusWorking34066.80
Ambulatory14528.49
Bedridden234.52
WHO stageStage 112224.06
Stage 29117.95
Stage 326552.27
Stage 4285.52
Socio-Demographic And Clinical Characteristics Of Adult HIV Patients On First-line ART In Gedeo Zone 2018

Prevalence Of Anemia

The prevalence of anemia was 34.8% (95% CI 30.1–39.8) while about 7.4%, 14.3%, and 13.1% of the patients had severe, moderate, and mild prevalence of anemia, respectively. The mean hemoglobin was 14.6 (SD=±10. 8), (95% CI 13.6–15.8). Among those anemic patients, 55% were females, the majority (80%) used 1E drug regimen, 40% were in the age group of 40–49 years, the majority (70%) of them had poor adherence to ART, 48% had opportunistic infections and 47.6% used isoniazid prophylaxis.

Factors Associated With Anemia

In the bivariate logistic regression type of regimen, occupation, educational status, INH, opportunistic infection, functional status, BMI (malnutrition) and adherence were statistically significant factors of anemia in adult HIV-infected patients on first-line ART. In the multivariable logistic regression, Using INH and bedridden functional status were statistically determinants of anemia (Table 2).
Table 2

Bivariate And Multivariable Logistic Regression Analysis Of Anemia And Associated Factors Among Adult People Living With HIV/AID Receiving Anti-Retroviral Therapy At Gedeo Zone, SNNPR, Ethiopia, 2018

VariableCrude OR (95% CI)Adjusted OR (95% CI)
Not AnemicAnemic
INH given
 No936911
 Yes175701.85(1. 25, 2.5)1.8(1.1, 2.9)*
Opportunistic infection
 No1356811
 Yes132711.99(0.7, 5.5)1.34(0.2, 10.4)
Adherence
 Good1941030.51(0.20, 1.31)0.56(0.2, 1.8)
 Poor703311
Functional status
 Working2068511
 Ambulatory58571.14(0.4,3.7)2.7(0.63, 11)
 Bedridden1152.75(0.83, 9)5.48(1.25, 23.8)*
BMI(malnutrition)
 Not malnourished22110611
 Malnourished54412.2(0.96, 5.1)1.65(0.95, 2.85)
Regimen*
 1b,1a &1c1350.24(0.03, 2.13)2.4(0.2,3.45)
 1d960.95(0.3,3.1)0.9(0.3,2.7)
 1e2251170.76(0.4,0.96)3.2(0.30.34.4)
 1f271911

Notes: *ART Regimen: 1a=d4T-3TC-NVP, 1b= d4T-3TC-EFV, 1c=AZT-3TC-NVP, 1d=AZT-3TC-EFV, 1e=TDF-3TC-EFV, 1f=TDF+3TC+NVP.

Abbreviations: Drug names: d4T, Stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; AZT, Zidovudine or azidothymidine; TDF, tenofovir disoproxil fumarate.

Bivariate And Multivariable Logistic Regression Analysis Of Anemia And Associated Factors Among Adult People Living With HIV/AID Receiving Anti-Retroviral Therapy At Gedeo Zone, SNNPR, Ethiopia, 2018 Notes: *ART Regimen: 1a=d4T-3TC-NVP, 1b= d4T-3TC-EFV, 1c=AZT-3TC-NVP, 1d=AZT-3TC-EFV, 1e=TDF-3TC-EFV, 1f=TDF+3TC+NVP. Abbreviations: Drug names: d4T, Stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; AZT, Zidovudine or azidothymidine; TDF, tenofovir disoproxil fumarate.

Discussion

The prevalence of anemia in this study was 34.8% (95% CI 30.1–39.8). This is within the range of different studies conducted on the prevalence of anemia among adult HIV patients taking ART (23% and 50% globally and 24% and 58% in Africa).11,12 In general, the prevalence of anemia tends to be higher in ART-naïve patients compared to ART users. In another study in Ethiopia, the prevalence of anemia among ART-naïve adult HIV patients was reported to reach up to 35%.17 The incidence of anemia ranges from 10% in people who have no HIV symptoms to 92% in individuals who have advanced AIDS.4 A study conducted in the very early years of HIV discovery had shown the overall prevalence of anemia to be about 28% among people with HIV infection in the pre-AIDS stage of the disease, whereas it could reach as high as 71% in the advanced or AIDS stage of the HIV disease.9 The prevalence of anemia in this study was lower than the findings of studies conducted in China,15 which was 39.2% and 52.3% in Arbaminch,15 but it is higher than the studies conducted in Debretabor Hospital,17 which was 23% and 16.2% in southwest Ethiopia.13 In this study, those patients who had bedridden functional status were 5.5 times more anemic than those who are working. INH users were 1.8 times more anemic. This finding is in line with a study conducted among adult HIV patients in Ethiopia: a hospital-based cross-sectional study.17 This might be due to that INH causes vitB6 deficiency which leads to anemia due to malabsorption of nutrients.

Conclusion

In this study, the prevalence of anemia was 34.8%. Functional status and INH were determinant factors of anemia. Based on the results, we recommend hospitals establish and rapidly expand awareness and counseling program to facilitate and motivate HIV-infected patients to improve their adherence and nutritional intake. Moreover, health care providers managing HIV patients should treat INH side effects and should prescribe iron and vitB6 supplementation to those malnourished and anemic patients.
  16 in total

1.  Prevalence and morphological types of anaemia and hookworm infestation in the medical emergency ward, Mulago Hospital, Uganda.

Authors:  Japheth E Mukaya; Henry Ddungu; Francis Ssali; Tim O'Shea; Mark A Crowther
Journal:  S Afr Med J       Date:  2009-12-07

2.  Hematological abnormalities in HIV-infected patients.

Authors:  Gil Cunha De Santis; Denise Menezes Brunetta; Fernando Crivelenti Vilar; Renata Amorim Brandão; Renata Zomer de Albernaz Muniz; Geovana Momo Nogueira de Lima; Manuela Emiliana Amorelli-Chacel; Dimas Tadeu Covas; Alcyone Artioli Machado
Journal:  Int J Infect Dis       Date:  2011-08-30       Impact factor: 3.623

Review 3.  Pathogenesis and pathophysiology of anemia in HIV infection.

Authors:  K A Kreuzer; J K Rockstroh
Journal:  Ann Hematol       Date:  1997 Nov-Dec       Impact factor: 3.673

4.  Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study.

Authors:  A M Levine; K Berhane; L Masri-Lavine; M Sanchez; M Young; M Augenbraun; M Cohen; K Anastos; M Newman; S J Gange; H Watts
Journal:  J Acquir Immune Defic Syndr       Date:  2001-01-01       Impact factor: 3.731

Review 5.  Interactions between nutrition and infection with human immunodeficiency virus.

Authors:  S L Gorbach; T A Knox; R Roubenoff
Journal:  Nutr Rev       Date:  1993-08       Impact factor: 7.110

Review 6.  Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations.

Authors:  L A Perkocha; G M Rodgers
Journal:  Am J Hematol       Date:  1988-10       Impact factor: 10.047

7.  Anemia in HIV infection: clinical impact and evidence-based management strategies.

Authors:  Paul A Volberding; Alexandra M Levine; Douglas Dieterich; Donna Mildvan; Ronald Mitsuyasu; Michael Saag
Journal:  Clin Infect Dis       Date:  2004-04-27       Impact factor: 9.079

8.  Prevalence of anaemia among HIV patients in rural China during the HAART era.

Authors:  Yantao Jin; Qingya Li; Xiangle Meng; Qianlei Xu; Jun Yuan; Zhengwei Li; Huijun Guo; Zhibin Liu
Journal:  Int J STD AIDS       Date:  2016-09-29       Impact factor: 1.359

9.  Anemia among adult HIV patients in Ethiopia: a hospital-based cross-sectional study.

Authors:  Hermela Melese; Molla Mesele Wassie; Haile Woldie; Abilo Tadesse; Nebiyu Mesfin
Journal:  HIV AIDS (Auckl)       Date:  2017-02-14

10.  Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.

Authors:  Lealem Gedefaw; Tilahun Yemane; Zewdineh Sahlemariam; Daniel Yilma
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more
  1 in total

1.  Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.

Authors:  Teklehaimanot Fentie Wendie; Getnet Mengistu
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.